<PAGE>
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
SEC File Number 0-30252
-------
CUSIP Number __________
Form 10-Q
For Period Ending: 3/31/00
- -------------------------------------------------------------------------------
PART I: REGISTRANT INFORMATION
- -------------------------------------------------------------------------------
Full Name of Registrant: BioLabs, Inc. ("BILB")
Address of Principal Executive Office: 1A-3033 King George Highway
Surrey, B.C. Canada V4P 1B8, (604) 542-0820
- -------------------------------------------------------------------------------
PART II: RULES 12b-25(b) AND (c)
- -------------------------------------------------------------------------------
The subject quarterly report on Form 10-Q is being filed herewith.
- -------------------------------------------------------------------------------
PART III: NARRATIVE
- -------------------------------------------------------------------------------
The Registrant timely completed its 10-Q for the period ended March 31, 2000.
Filing yesterday was delayed by transmission errors to the printer for
Edgarizing format. The filing was made yesterday but accepted as of this
morning.
<PAGE>
- -------------------------------------------------------------------------------
PART IV: OTHER INFORMATION
- -------------------------------------------------------------------------------
(1) Name and telephone number of person(s) to contact in regard to this
notification
Larry Pasemko (604) 542-0820
(2) Have all other periodic reports required under section 13 or 15(d) of the
Securities Exchange Act of 1934 or section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period
that the Registrant was required to file such report(s) been filed? If
the answer is no, identify report(s).
/X/ Yes / / No
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected
by the earnings statements to be included in the subject report or
portion thereof?
/ / Yes /X/ No
If so, attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
Not applicable.
-2-
<PAGE>
BIOLABS, INC.
(Name of Registrant specified by charter)
has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Dated: May 16, 2000
BIOLABS, INC.
By: /s/ Larry Pasemko
-----------------
Larry Pasemko
Vice President
-3-
